#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Nuria Barquero Email
Head Preclinical Toxicology . ARTHEx Biotech
Paterna,
LocationPrimary Email
How to contact Nuria Barquero
Join and see Nuria's contact info for free!Current Roles
Employees:
34Revenue:
$5.3MAbout
ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. \n \nARTHEx has developed its proprietary technology, the ENTRY ™ platform, that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevant tissues in pharmacological quantities, in order to treat diseases in which microRNAs play a key role.\n\nThe first investigational product from this platform is ATX-01, an antimiR in preclinical development for Myotonic Dystrophy Type 1 (DM1). DM1 is an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000) with no cure, nor approved treatment to date. ATX-01 is a first-in-class disease-modifying therapy that addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis.\n\nTo learn more about Arthex Biotech, please visit us at www.arthexbiotech.comARTHEx Biotech Address
Paterna, null
Spain